Irinotecan
Neuroendocrine Carcinoma
National Cancer Institute (NCI)Small moleculePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 81/ 100
Competitive context
28 Active assets in the Neuroendocrine Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE National Cancer Institute (NCI) | Phase 2 | B |
Cyclophosphamide National Cancer Institute (NCI) | Phase 2 | B |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 2 | B |
Everolimus AIO-Studien-gGmbH | Phase 2 | B |
Epirubicin Ochsner Health System | Phase 2 | B |
View all 38 →
Same molecule, other indications
Irinotecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →